Blood matrix metalloproteinase 9 (MMP9) is a predictive biomarker for cardiac diseases and disorders
AssigneeUniversity of Rochester
InventorsScott J. Cameron, Frederick Ling
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods useful for the assessment, diagnosis, and treatment of myocardial infarctions.
Claims19
A method of diagnosing ST-elevation myocardial infarction (STEMI) in a subject, the method comprising:
- a. detecting the level of MMP9 in a biological sample obtained from the subject;
- b. comparing the level of MMP9 in the biological sample to a control level of MMP9;
- and
- c. diagnosing the subject with STEMI when MMP9 is elevated in the biological sample as compared to the control level.
A method of diagnosing non-ST-elevation myocardial infarction (NSTEMI) in a subject, the method comprising:
- a. detecting the level of MMP9 in a biological sample obtained from the subject;
- b. comparing the level of MMP9 in the biological sample to a control level of MMP9;
- and
- c. diagnosing the subject with NSTEMI when MMP9 is differentially expressed in the biological sample as compared to the control level.
A kit for distinguishing between STEMI and NSTEMI, the kit comprising a reagent for measuring the level of MMP9 in a biological sample of a subject.
A method of treating STEMI in a subject who has been identified as having a differentially expressed level MMP9, comprising administering an effective STEMI treatment to the subject.
A method of treating NSTEMI in a subject who has been identified as having a differentially expressed level of MMP9, comprising administering an effective NSTEMI treatment to the subject.
Dependencies are inferred from the claim text.